efferon-lps-2021-01
Проводит Efferon JSC
Страница компанииLipopolysaccharide Adsorption At Septic Shock with Efferon LPS Extracorporeal Blood Adsorbers
Постоянная ссылка: https://clinomir.ru/trials/nct/NCT04827407/
Источник: ClinicalTrials.gov (U.S. National Library of Medicine). Что откуда
Простыми словами
Словарь терминов- Исследование завершено, новых участников не набирают.
- Возраст участников: 18–75 лет. Остальные условия — в блоке «Кто может участвовать».
- По плану участвуют 58 чел. во всех странах исследования.
- Центров в реестре: 4 в одном городе. Список — ниже на странице.
- Плановая дата окончания (08.2022) уже прошла.
Пересказ собран автоматически из данных реестра, без оценки пользы и рисков. Подробно о рисках и пользе рассказывает врач центра перед подписанием согласия.
Кто может участвовать
Полный текст критериев (на английском, как в ClinicalTrials.gov) · включение: 11 · невключение: 10
Критерии включения
- Age ≥18 years
- Established diagnosis of Gram-negative septic shock according to SEPSIS-3 criteria
- The immediate post-operative period (no more than 24 hours after surgery)
- Hypotension requiring vasopressor support: the need for at least one of the vasopressors listed below at the dose listed below for at least 2 hours continuously and not more than 12 hours.
- Norepinephrine> 0.05 µg/kg/min
- Dopamine> 10 µg/kg/min
- Phenylephrine> 0.4 µg/kg/min
- Adrenaline > 0.05 µg/kg/min
- Vasopressin> 0.03 units/min Vasopressin (any dose) in combination with another vasopressor listed above
- The patient must have received intravenous infusion therapy of at least 30 ml/kg administered within 24 hours of inclusion.
- The patient's condition allows therapy with the Efferon LPS device for at least 4 hours.
Критерии невключения
- Lack of adequate antimicrobial chemotherapy
- Identifying the criteria for non-inclusion;
- A patient may voluntarily withdraw from a trial at any time after giving informed consent and before the trial is completed. The investigator may also withdraw a participant from the trial at any time at his or her discretion and for any of the following reasons:
- Reasons for a participant's withdrawal from the trial will be recorded and may include, amongst others, the following
- Withdrawal of consent to participate in the trial by the participant.
- The development of an adverse event, including a serious one; individual intolerance to the investigational product, hypersensitivity to the components of the product due to which further participation in the trial is not possible.
- Continued participation in the trial is not, in the researcher's opinion, in the participant's health interests.
- The presence of deviations from the plan which, in the opinion of the Sponsor and Investigator, require the withdrawal of the participant from the trial.
- A positive pregnancy test result at any time during the test.
- When any participant withdraws from a trial, the reason for the withdrawal should be documented.
Источник: ClinicalTrials.gov, NCT04827407 · запись обновлена в реестре 19 сентября 2024.
Дизайн и результаты
Что измеряют — первичные конечные точки (1), вторичных — 3
- Effect of the Efferon LPS hemoperfusion in extracorporeal therapy in patients with abdominal sepsis complicated by septic shock — 1-14 days
Цель исследования
Sepsis is a global healthcare burden sepsis, it reaches 20-30 million cases annually (WHO data). Numerous studies have shown that extracorporeal hemoperfusion therapies that eliminate endotoxin and\\or excess of cytokines improve treatment outcomes in patients with septic shock. The main purpose of the study is to obtain new data on the efficacy and safety of the Efferon LPS device in extracorporeal therapy in patients with abdominal sepsis complicated by septic shock.
Где проходит
4 центра в 1 городеОткуда эта информация
-
ClinicalTrials.gov (U.S. National Library of Medicine) · NCT04827407 Официальный реестр (США) · загружено 9 ноября 2026Номер протокола, название, цель, статус, сроки, число участников, спонсор, центры
Сведения сведены и нормализованы порталом «Клиномир»: названия компаний и центров приведены к одному написанию. Нашли ошибку? Напишите нам — исправим.